Irvine Scientific to exclusively distribute stem cell tech

By The Science Advisory Board staff writers

September 29, 2020 -- Fujifilm Irvine Scientific said it has become the exclusive worldwide distributor of cellnest, a recombinant peptide attachment substrate that's designed to provide optimal adhesion and proliferation of stem cells for cell and gene therapy research.

Cellnest, which was designed and manufactured by Fujifilm Irvine Scientific's parent company Fujifilm, mimics the extracellular matrix and enables the adhesion, expansion, and potential differentiation of stem cells, according to the vendor. It's compatible with any adherent cell type that binds to the Arg-Gly-Asp (RGD) domain, an amino acid sequence within the extracellular matrix protein fibronectin that mediates cell attachment, Fujifilm Irvine Scientific said.

Cellnest is a companion product to its Prime-XV stem cell culture media portfolio and is also well-suited for the attachment and growth of mesenchymal stem cells, according to the company.

Science serves society, a crucial concept for gene therapy governance
With a focus on science and society, the American Society of Gene & Cell Therapy Policy Summit commenced on September 24. The ensuing discussion revealed...
New in vitro models reveal importance of lung stem cells in SARS-CoV-2 infection
Researchers have developed a new 2D lung organoid in vitro model as a physiologically relevant platform to aid drug development and explore the pathogenesis...
Curi Bio launches ComboMat to aid preclinical drug development
Curi Bio released its new proprietary ComboMat platform, a human induced pluripotent stem cell cardiomyocyte maturation technology with applications in...
Magenta to explore targeted gene editing to cure HIV
Clinical-stage biotechnology company Magenta Therapeutics has joined a broad-based research effort to explore gene- and cell-based approaches to cure...
Cartesian begins trial of RNA-based cell therapy for COVID-19
Cartesian Therapeutics has initiated a phase I/II clinical trial for the use of its Descartes-30 lead RNA-engineered mesenchymal stem cell therapy in...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter